# Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

> **NCT02717195** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 1098 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Olanzapine
- **DRUG:** Lu AF35700
- **DRUG:** Lu AF35700

## Key facts

- **NCT ID:** NCT02717195
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2018-08-30
- **Final completion:** 2018-10-08
- **Target enrollment:** 1098 (ACTUAL)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02717195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02717195, "Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02717195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*